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could extend the G0/G1 phase and block cell prolifera-
tion in RMCs. Dual-luciferase assay results showed that 
there were binding sites of miR-34a at 3′-UTR of platelet-
derived growth factor receptor-β (PDGFR-β). MiR-34a can 
inhibit PDGFR-β protein expression at a post-transcrip-
tional level, suppress Ras/MAPK signaling pathways, and 
down-regulate expression of cell cycle proteins at the G0/
G1 phase, such as cyclin D1, CDK4/CDK6. In addition, 
miR-34a may also inhibit RMC proliferation by directly 
targeting cyclin E and CDK2. MiR-34a inhibits exogenous 
stimuli-induced proliferation of mesangial cells. Expres-
sion levels of phospho-PDGFR-β and phospho-MEK1 (an 
important downstream molecule in PDGFR-β-induced 
signaling pathway) were significantly increased in the anti-
Thy-1 nephritis rat model. These results suggest that miR-
34a may regulate RMC proliferation by directly inhibiting 
expressions of PDGFR-β, MEK1, and cell cycle proteins, 
cyclin E and CDK2.
Keywords Mesangial proliferative glomerulonephritis 
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Introduction
Mesangial proliferative glomerulonephritis (MsPGN) can 
be divided into IgA nephropathy and non-IgA nephropathy, 
which show diffuse hyperplasia of glomerular mesangial 
cells (GMCs) and different degrees of extracellular matrix 
(ECM) accumulation [1, 2]. Inhibition of mesangial cell 
proliferation is an important treatment strategy in prolifer-
ating glomerular diseases [3].
Anti-Thy1 nephritis is a rat model of human mesangial 
proliferative glomerulonephritis, involving a combination 
Abstract The main pathological characteristic of glo-
merulonephritis is diffuse mesangial cell proliferation. 
MiR-34a is associated with the proliferation of various 
organs and cancer cells. However, the role of miR-34a in 
renal proliferation diseases is not clear. Therefore, this 
study aimed to elucidate the mechanism of miR-34a in the 
regulation of renal mesangial cell proliferation. The miR-
34a expression level at different time points in an anti-Thy1 
mesangial proliferative nephritis rat model was determined 
by qRT-PCR. The cell proliferation rate and cell cycle 
changes were measured in the in vitro cultured rat mesan-
gial cells (RMCs). Our results suggested that miR-34a 
expression was negatively correlated with the degree of cell 
proliferation in the anti-Thy1 nephritis model. MiR-34a 
D. Chen · Y. Mei · W. Geng · Q. Hong · Z. Feng · G. Cai · 
H. Zhu · S. Shi · X.-Y. Bai (*) · X. Chen (*) 
State Key Laboratory of Kidney Diseases (2011DAV00088), 
Department of Nephrology, Chinese PLA Institute 
of Nephrology, National Clinical Research Center for Kidney 
Disease (2013BAI09B05), Chinese PLA General Hospital,  





Medical College, NanKai University, Tianjin,  
People’s Republic of China
Y. Li 
Department of Nephrology, Third Hospital, Hebei Medical 
University, Shijiazhuang, People’s Republic of China
J. Yang 
Department of Nephrology, Daping Hospital, Research Institute 
of Surgery, Third Military Medical University, Chongqing, 
People’s Republic of China
4028 D. Chen et al.
1 3
of Thy1 antibody and Thy1 antigen in mesangial cells. 
Macromolecular immune complexes are formed in situ and 
deposited in the mesangial area, leading to mesangial cell 
proliferation and inflammation [4, 5]. These inflammatory 
mediators in turn stimulate activation, shrinkage, and pro-
liferation of mesangial cells; release a variety of inflamma-
tory mediators and ECM components [6, 7]; and aggravate 
inflammation, all of which result in glomerular damages, 
including damage to the molecular barrier and charge bar-
rier of the filtration membrane, and proteinuria [8].
MicroRNAs (miRNAs) are 21- to 25-nucleotide (nt)-
long, single-stranded RNA molecules that serve as post-
transcriptional regulators of gene expression in eukaryotes 
and that do not code for any protein [9–11]. miRNAs can 
regulate the expression of thousands of proteins by degrad-
ing target mRNA or inhibiting translation as a result of 
complementary matching between miRNAs and specific 
sites in target genes [12]. miRNAs are widely involved in 
a series of biological functions and are closely associated 
with human diseases, including kidney diseases [13].
miR-34 was first found in the worm Caenorhabditis 
elegans in 2001 [14]. In recent years, it has been shown 
that miR-34a is involved in tumor proliferation of neuro-
blastoma [15, 16], colon cancer [17], uveal melanoma [18], 
brain tumors [19], and cervical cancer [20] through regula-
tion of different target genes. However, the role of miR-34a 
in mesangial proliferative glomerulonephritis is unclear. 
We thus aimed to investigate the role of miR-34a in renal 
proliferation diseases.
Materials and methods
Anti-Thy1 nephritis animal model
Male Wistar rats (Beijing Vital River Laboratory Animal 
Technology Co., Ltd., Beijing, China) weighing between 
200 and 220 g were randomly allocated to the control and 
anti-Thy1.1 groups. Anti-Thy1.1 nephritis was induced by 
a single intravenous injection of a monoclonal anti-Thy1 
antibody (2.5 mg/kg) produced by OX-7 cells. Controls 
were injected with an identical volume of normal saline. 
Anti-Thy1-treated animals were killed on days 3, 5, 7, 10, 
and 14 post-injection (n = 3 per time point), and the con-
trol animals were killed on day 0 (n = 3). All rats were pro-
vided a diet of standard laboratory chow and free access to 
water. The renal tissues were examined by routine periodic 
acid-Schiff staining.
Immunohistochemical analysis and evaluation
The renal tissues were fixed in formalin and embedded 
with paraffin. The histologic paraffin sections were cut to 
3- to 4-μm thickness and mounted on poly-l-lysine-coated 
slides. Endogenous peroxidase was blocked with 3 % 
hydrogen peroxide. The sections were heated in a micro-
wave oven for 10 min in sodium citrate buffer (pH 6.0), 
incubated with 1.5 % normal goat serum for 20 min, and 
incubated overnight with 1:100 diluted primary antibody 
(Ki-67). For a negative control, the sections were incubated 
with PBS. After removal of unbound primary antibody, the 
sections were incubated with a biotinylated secondary anti-
body for 60 min at room temperature. The sections were 
rinsed and incubated with avidin-biotinylated horseradish 
peroxidase (Vectastain Elite ABC Kit; Vector Laborato-
ries, USA) for 60 min. Incubation with 3,3-diaminoben-
zidine tetrahydrochloride was performed for 10 min as a 
substrate chromogen solution to produce a brown color. 
Finally, the sections were counterstained with hematoxy-
lin. Twenty glomeruli per section at each time point were 
evaluated under high-power light microscopy (×400) in a 
blinded fashion. The Ki67 labeling index was calculated as 
the number of Ki-67-positive cells to total glomerular cells.
Cell culture and transfection
Rat mesangial cells (RMCs) were purchased from the 
American Type Culture Collection (ATCC). Cells were 
cultured in RMPI 1640 medium (Gibco, USA) containing 
10 % fetal bovine serum (FBS; Hyclone, Canada), 100 U/
ml penicillin, and 100 μg/ml streptomycin (Gibco, USA) 
at 37 °C in a humidified incubator with an atmosphere con-
taining 5 % CO2. Trypsin (0.25 %) was used for cell pas-
sages. RMCs (~50 % confluence) were transfected with 
miR-34a mimics (Dharmacon, Thermo Scientific, USA; 
cat. no. C-300551-07), miRNA control (Dharmacon cat. 
no. CN-001000-01), siPDGFR-β or siCon (Table 1) using 
jetPRIME (Polyplus-transfection, USA) for 48 h, followed 
by determination of protein and RNA levels.
Quantitative reverse-transcriptase polymerase chain 
reaction (qRT-PCR)
TaqMan miRNA assays were performed to quantify mature 
miR-34 levels. Briefly, cDNA was synthesized using 
Taqman RT reagents (Applied Biosystems, USA), followed 
by TaqMan-based quantitative PCR using specific mirVana 
Table 1  siRNA sequence
Target gene 5′ → 3′
siPDGFR-β Sense GAC GCU GCA UGA GAA GAA ATT
Antisense UUU CUU CUC AUG CAG CGU CTT
siCon Sense UUC UCC GAA CGU GUC ACG UTT
Antisense ACG UGA CAC UGG CGG AGA ATT
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qRT-PCR primer sets. The primary transcript levels of 
PDGFR-β, cyclin D1, cyclin E, CDK2, CDK4, CDK6, and 
p27kip1 (Table 2) were determined with the SYBR Green 
Real-time qPCR Master Mix (Toyobo, Japan). The qRT-
PCR analyses were conducted using an Applied Biosys-
tems ABI Prism 7300 Sequence Detection System, and 
qRT-PCR reactions were performed using the following 
parameters: 95 °C for 10 min, followed by 40 cycles at 
95 °C for 15 s and 60 °C for 1 min. The relative RNA levels 
were calculated using the ΔΔCt method and normalized to 
U6 snRNA control for rat miR-34a or to GAPDH for RMC 
mRNAs. Sequence-specific primers for the indicated genes 
were designed using the Primer Premier software, version 
5.0 (PREMIER Biosoft International, USA).
Cell proliferation assay
As a measure of cell proliferation, the number of viable 
cells was detected using the Cell Counting Kit-8 (Beyo-
time, China). RMCs were seeded in 96-well plates at 
a density of 2,000/well, synchronized by incubation in 
FBS(−) medium for 12 h, and then transfected with miR-
34a mimics or a miRNA control. At 24, 48, and 72 h post-
transfection, the number of viable cells was measured by 
recording the optical density at 450 nm and generating 
growth curves. Experiments were performed in triplicate, 
and sextuplet wells were used.
Cell cycle analysis
RMCs were seeded in six-well plates at a density of 
1.0 × 105/well, synchronized by incubation in FBS(−) 
medium for 12 h, and then transfected with miR-34a mim-
ics or a miRNA control for 48 h. The cells were washed 
twice with PBS, suspended in 75 % ethanol, and fixed by 
incubation in 75 % ethanol at 4 °C overnight. Fixed cells 
were collected by centrifugation, washed with PBS, treated 
with RNase (50 μg/ml; Sigma, USA), and stained with 
propidium iodide (50 μg/ml; Sigma, USA). A FACS flow 
cytometer (BD Co., USA) was used to determine cellular 
DNA contents. The percentage of cells in G0/G1, S, and 
G2/M phases were determined using the Cell FIT Cell 
Cycle Analysis software (version 2.01.2; BD).
Western-blot analysis
Proteins were extracted from RMCs using RIPA lysis 
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.5 % 
deoxycholate, 1 % Nonidet P-40, 0.1 % SDS, 1 mM PMSF, 
and protease cocktail at 1 μg/ml). Protein concentrations 
were determined using a BCA kit (Pierce, USA). Protein 
samples (60 μg per lane) were separated by 10 or 12 % 
SDS-PAGE electrophoresis and transferred to NC mem-
branes. After staining with Ponceau S, the membranes 
were incubated overnight in 5 % non-fat milk at 4 °C, 
followed by incubation with primary antibodies against 
PDGFR-β, p-PDGFR-β, and p27kip1 (Cell Signaling Tech-
nology, USA); cyclin D1, cyclin E, CDK2, CDK4, CDK6, 
ERK1/2, and p-ERK1/2 (Abcam, USA); MEK1 and 
p-MEK1 (Abcam, USA); Raf1, p-Raf1 and K-ras(Abnova, 
USA); or β-actin (Sigma, USA). Immunoreactive bands 
were visualized using ECL reagent (Santa Cruz Biotech-
nology), according to the manufacturer’s instructions, and 
exposure to X-ray film. Protein band intensities were quan-
tified using Quantity One software (Bio-Rad, USA).
Plasmids
PDGFR-β, cyclin E, and CDK2 cDNAs were amplified from 
RMCs by PCR. The 1521-bp fragment of the PDGFR-β 3′-
UTR, the 426-bp fragment of the cyclin E 3′-UTR, or the 
999-bp fragment of the CDK2 3′-UTR (Table 3), all con-
taining the miR-34a targeting sequence, was cloned into 
Table 2  Real-time qPCR primers for genes
Target gene 5′ → 3′ Product
PDGFR-β Sense ACC ATG CGG GCC TTC CAT 
GC
152 bp
Antisense TTT GGC TGA GGC ATG CCC 
CG
Cyclin D1 Sense CTG CAG CTT CTG GGG GCC 
AC
119 bp
Antisense AGC AAC TCC TCG GGG CGG 
AT
Cyclin E Sense ATT CAG CGT GCG TGG ACC 
CC
119 bp
Antisense GGA GGC TCT GGG CGG TCT 
GA
CDK2 Sense TTC CCC AAG TGG GCT CGG 
CA
128 bp
Antisense GCC AGG GCT GCT TTG GCT 
GA
CDK4 Sense TCC GAG CCC TGC AGC ACT 
CTT A
152 bp
Antisense AGG CTG CCA CTT CAG CAA 
GGT T
CDK6 Sense ACT TCG GCC TTG CCC GCA 
TC
79 bp
Antisense TCC GGG GCT CGG TAC CAC 
AG
p27 Sense CAC CCC AAG CCT TCC GCC 
TG
108 bp
Antisense GCG CTG GCT CGC TTC TTC 
CA
GAPDH Sense GGC ATG GAC TGT GGT CAT 
GAG
87 bp
Antisense TGC ACC ACC AAC TGC TTA GC
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the psiCHECK dual-luciferase reporter plasmid (Promega, 
USA; cat. no. C8021) to produce psiCHECK-WT-PDGFR-β, 
psiCHECK-WT-cyclin E, or psiCHECK-WT-CDK2, respec-
tively, using PCR. Sequence-specific primers for the indicated 
genes were designed using the Primer Premier software, ver-
sion 5.0. The sequences of all constructs were verified.
Dual-luciferase reporter assay
For reporter assays, RMCs were cultured to approximately 
80 % confluence in a 24-well plate and then co-transfected 
with a dual-luciferase reporter plasmid (psiCHECK-
PDGFR-β, or psiCHECK-cyclin E, or psiCHECK-CDK2) 
and miR-34a mimics for 48 h. The activities of firefly and 
Renilla luciferases were determined using the Dual-Lucif-
erase Reporter Assay System (Promega cat. no. E1910), 
and firefly luciferase activity was normalized to that of 
Renilla luciferase.
Statistical analyses
Measurement data are expressed as mean ± SEM, unless 
otherwise stated. Statistical analyses were performed using 
the SPSS 15.0 software package (SPSS, Inc., USA). Com-
parison among groups was conducted with ANOVA. Sta-
tistical differences were evaluated with analysis of vari-
ance. A p value <0.05 denoted a statistically significant 
difference.
Results
Pathological changes in rat model of anti-Thy1 mesangial 
proliferative glomerulonephritis
We injected Thy1 antibody into Wistar rats to create an 
anti-Thy1 mesangial proliferative glomerulonephritis rat 
model. Following injection of anti-Thy1 antibodies, par-
tial complement-dependent mesangiolysis appeared on 
day 3; mesangial cell proliferation and ECM accumula-
tion occurred on day 5 and peaked on day 7. On day 10, 
recovery from glomerular injury began to decrease, and 
ECM accumulation attenuated on day 14 (Fig. 1a). We 
also detected the expression changes of cell prolifera-
tion marker Ki-67 by immunohistochemistry (Fig. 1b, c). 
We found higher levels of Ki-67 at every time point dur-
ing anti-Thy1 nephritis compared with the control, which 
suggests that the cell cycle remained active from days 3 to 
10. Ki-67 increased on days 3 and 5, peaked on day 7, and 
decreased from days 10 to 14. This suggests that cell cycle 
activity increased from days 3 to 7 and subsequently gradu-
ally decreased from days 10 to 14 (p < 0.05)(Fig. 1b, c).
MiR-34a expression in the kidney tissues of anti-Thy1 
nephritis rat model
MiR-34a expression was detected in the kidney tissues of 
the anti-Thy1 nephritis rat model at various time points 
(days 3, 5, 7, 10, and 14) by real-time qPCR. Compared 
with the normal group, miR-34a expression gradually 
decreased as pathological changes progressed from day 
3 (p < 0.05). Expression levels and pathologic outcomes 
became normal on day 14 (p < 0.05) (Fig. 2).
Effect of miR-34a on mesangial cell proliferation rate 
and cell cycle
RMCs were transfected with miR-34a mimics (mimics 
group) or a miRNA-negative control (Con group), and the 
proliferation rate of miR-34a mimic-transfected cells was 
determined using the Cell Counting Kit-8 (Fig. 3a). Prolif-
eration of RMCs was reduced at 24 h (p > 0.05), signifi-
cantly reduced at 48 h (p < 0.05), and more obvious at 72 h 
(p < 0.01) in miR-34a mimics-transfected group, compared 
with the normal group and the miRNA-negative control 
group, indicating that miR-34a mimics influence RMC pro-
liferation. Cellular DNA content was further assessed by 
flow cytometry. The results showed that miR-34a mimics 
markedly extended the G0/G1 phase and reduced the G2/M 
phase (Fig. 3b; Table 4), compared with the normal group 
and the miRNA-negative control group (p < 0.05).
Influence of miR-34a on possible target gene, PDGFR-β
By using online biology software miRGen (http://www.
diana.pcbi.upenn.edu/miRGen.html), we hypothesized that 
PDGFR-β may be a target gene of miR-34a (Table 5). To 
confirm whether miR-34a interacts with the 3′-UTR of 
PDGFR-β and regulates target gene expression at a post-
transcriptional level, we cloned the 3′-UTR fragment 
Table 3  PCR primers for 3′-UTR fragments
Target gene 5′ → 3′ Product
PDGFR-β Sense CTG CCC AGG ACC TCT GGC 
TG
2548 bp
Antisense CAG AAG GGC CTCC CAG GAG 
GG
CDK2 Sense TCT CTG GGC CAG CCG GTT 
CT
999 bp
Antisense ACA ACA CGG GGT GGG AGA 
AGG A
Cyclin E Sense TCC TCC TCC GAG TGG GGT 
CCT
426 bp




of PDGFR-β into the dual-luciferase reporter vector 
psiCHECK to construct a psiCHECK-PDGFR-β plas-
mid, which was co-transfected into RMCs with miR-34a 
mimics or miRNA-negative control. MiR-34a mimics 
significantly down-regulated firefly luciferase activity in 
psiCHECK-PDGFR-β-transfected cells (p < 0.05) (Fig. 4a). 
To further confirm the direct action of miR-34a, levels 
of PDGFR-β mRNA and protein were determined in the 
miR-34a mimics-transfected cells. There was no signifi-
cant difference between miR-34a mimic-transfected cells 
Fig. 1  Pathological changes 
and expression of Ki-67 in 
anti-Thy1 nephritis model 
rats. a Periodic acid-Schiff 
stain (original magnification 
×400). b Expression of Ki-67 
in anti-Thy1 nephritis model 
rats. Expression of Ki-67 was 
detected with immunohisto-
chemistry analysis. c Ki-67 
labeling index was calculated 
by Ki-67-positive cells to total 
glomerular cells. N: normal 
group rats; day 3, 5, 7, 14, and 
28: anti-Thy1 nephritis rats at 
day 3, 5, 7, 14, 28, separately. 
*p < 0.05 vs. N (normal group 
rats). #p < 0.05 vs. Day7 group, 
n = 6
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and control cells in terms of PDGFR-β mRNA expression 
level (p > 0.05) (Fig. 4b). Western blot showed that protein 
expressions of PDGFR-β and phospho-PDGFR-β were sig-
nificantly decreased in the miR-34a mimic-transfected cells 
compared with the control cells (p < 0.05) (Fig. 4c). These 
results indicate that PDGFR-β may be a target gene of 
miR-34a. Moreover, miR-34a likely inhibits PDGFR-β pri-
marily through post-transcriptional regulation. At the same 
time, we detected protein expressions of PDGFR-β and 
phospho-PDGFR-β (activated PDGFR-β) in the anti-Thy-1 
nephritis rat model. Compared with day 0, on day 7 (the 
most obvious pathological change), phospho-PDGFR-β 
was significantly increased (p < 0.05) (Fig. 4d), indicating 
that PDGFR-β plays a key regulative role in proliferation 
development in the anti-Thy-1 nephritis.
Effects of miR-34a on expressions of cell cycle-related 
mRNAs and proteins
Compared with the normal group and Con group, cyclin 
E mRNA level was significantly decreased (p < 0.05), and 
that of P27kip1 was significantly increased (p < 0.05); how-
ever, there were no changes in mRNA levels of cyclin D1, 
CDK2, CDK4, or CDK6 in the miR-34a-transfected cells 
(p > 0.05) (Fig. 5a). Levels of cell cycle proteins (cyclins 
D1 and E), CDK proteins (CDK2, CDK4, and CDK6), 
Fig. 2  MiR-34a expression levels were detected with qRT-PCR 
in anti-Thy1 model rats. *p < 0.05 vs. N (normal group), n = 6; 
#p < 0.05 vs. day 7 group, n = 6
Fig. 3  Changes of proliferation activity and cell cycle in the RMCs 
transfected with miR-34a mimics. a Proliferation activity of RMCs 
was detected by Cell Counting Kit-8 after transfection with miR-
34a mimics or miRNA-negative control. *p < 0.05 vs. normal (nor-
mal group) and Con (miRNA-negative control group) at 48 h, n = 3; 
#p < 0.05 vs. normal group and Con group at 72 h, n = 3. Mimics: 
miR-34a mimics. b Analysis results of cell cycle by flow cytometry 




and CKI (p27kip1) were also determined. Levels of cyclin 
D1, cyclin E, CDK2, CDK4, and CDK6 were significantly 
reduced (p < 0.05), while that of p27kip1 was significantly 
increased (p < 0.05) in the miR-34a-transfected cells, com-
pared with the normal group and Con group (Fig. 5b). Two 
cell-cycle complexes, cyclin D1/CDK4/CDK6 and cyclin 
E/CDK2, mainly play a role during the mid G0/G1 stage. 
Previous studies showed that cyclin D1 [21], CDK4 [9], and 
CDK6 [21, 22] are target genes of miR-34a. Therefore, we 
hypothesized that cyclin E and CDK2 may be target genes 
of miR-34a. We cloned the 3′-UTRs of cyclin E and CDK2 
into psiCHECK-2 to construct two plasmids, psiCHECK-
cyclin E and psiCHECK-CDK2. Both miR-34a mimics 
and the two plasmids were co-transfected into cells. MiR-
34a significantly down-regulated firefly luciferase activity 
in psiCHECK-2-cyclin E-transfected cells (Fig. 5c) and 
psiCHECK-2-CDK2-transfected RMC cells (Fig. 5d), sug-
gesting cyclin E and CDK2 to be target genes of miR-34a.
Influence of miR-34a on the molecules in the Ras/MAPK 
signaling pathway
RMCs were transfected with miR-34a mimics or a miR-
negative control, and expression levels of two key targets 
in the Ras/MAPK signaling pathways were determined. 
The total MEK1 protein level was significantly decreased 
(p < 0.05), but those of Raf1 and ERK1/2 were unchanged 
(p > 0.05) (Fig. 6a), indicating that MEK1 is the target 
gene of miR-34a, which has also been demonstrated by 
others [23]. Moreover, protein levels of K-ras, p-Raf1, 
p-MEK1, and p-ERK1/2 were significantly down-regulated 
(p < 0.05) (Fig. 6a). We also detected MEK1, which is the 
most important molecule in the RAS/MAPK signal path-
way in the anti-Thy1 mesangial proliferative glomerulone-
phritis rat model. Compared with 0 days, phospho-MEK1 
at 7 days was significantly increased (p < 0.05) (Fig. 6b). 
The above results suggested that Ras/MAPK signaling 
pathway plays a key role in the development of rat mesan-
gial proliferative glomerulonephritis.
Effects of siPDGFR-β on RMC cell cycle, cell cycle 
proteins, and the Ras/MAPK signaling pathway
To further determine whether miR-34a can directly target 
PDGFR-β, we evaluated the influences of siPDGFR-β on 
the cell cycle, cell cycle-related proteins, and Ras/MAPK 
signaling pathway molecules using an RNAi technique. 
After siPDGFR-β transfection, proliferation of RMC cells 
was suppressed (Fig. 7a; Table 6); and the G0/G1 phase was 
extended and the G2/M phase was reduced (Fig. 7b). Protein 
Table 4  The percentage of mesangial cells in G0/G1, S, and G2/M 
phases
Normal normal group, Con miRNA-negative control group, Mimics 
miR-34a mimics group
* p < 0.05 vs. normal and Con, n = 3
G0–G1 (%) S (%) G2-M (%)
Normal 63.86 ± 2.31 23.16 ± 1.62 12.98 ± 1.57
Con 61.07 ± 1.74 24.14 ± 2.26 14.79 ± 1.30
Mimics 75.81 ± 2.19* 16.68 ± 1.24* 7.52 ± 0.79*
Table 5  The combined sequence of miR-34a target PDGFR-β in 
3′UTR
From offset 4998 to 5019 | Folding energy = -29.000000 Kcal/mol






From offset 3749 to 3770 | Folding energy = -36.000000 Kcal/mol






From offset 4888 to 4909 | Folding energy = -28.600000 Kcal/mol




||||| || |||| |||||||
UGUUGGUCGAUUCUG-UGACGGU 
From offset 4452 to 4473 | Folding energy = -25.600000 Kcal/mol




|||| || || ||||||
UGUUGGU-CGAUUCUGUGACGGU 
From offset 4551 to 4572 | Folding energy = -27.600000 Kcal/mol




||| ||||| || ||||||
UGUUGGUC---GAUUC-UGUGACGGU 
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levels of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 
were significantly decreased after siPDGFR-β transfection 
(p < 0.05) (Fig. 7c). Levels of the Ras/MAPK signaling 
pathway proteins, K-ras, Raf1, MEK1, and ERK1/2, were 
determined. There were no changes in protein levels of total 
Raf1, MEK1, and ERK1/2 (p > 0.05) (Fig. 7d). However, the 
protein levels of K-ras, p-Raf1, p-MEK, and p-ERK1/2 were 
significantly decreased (p < 0.05) (Fig. 7d). These results 
indicate that siPDGFR-β directly suppressed PDGFR-β and 
then influenced the cell cycle through the Ras/MAPK sign-
aling pathway. The actions of miR-34a and siPDGFR-β on 
both PDGFR-β and the cell cycle were similar.
MiR-34a suppressed the proliferation of RMCs that were 
stimulated by 20 % FBS
We have demonstrated that miR-34a can inhibit the pro-
liferation of normal mesangial cell by directly inhibit-
ing target gene PDGFR-β. Here, we stimulated mesangial 
cell proliferation with exogenous factors (20 % FBS), and 
then observed if miR-34a could antagonize this phenom-
enon. The results showed that, after 20 % FBS treatment, 
the proliferation rate of cultured mesangial cells was sig-
nificantly higher than 10 % FBS-treated mesangial cells 
(p < 0.05) (Fig. 8a). After miR-34a mimics transfection, 
Fig. 4  Effect of miR-34a on 
expression of PDGFR-β. a 
Effect of miR-34a on expression 
of PDGFR-β by using Dual-
Luciferase Reporter plasmids. 
The 3′-UTR of PDGFR-β was 
inserted into 3′ end of luciferase 
coding sequence in psiCHECK 
vector and recombinant plasmid 
was transfected into RMCs with 
miR-34a mimics or miRNA-
negative control. Firefly lucif-
erase activity was normalized 
to Renilla luciferase activity. 
*p < 0.01 vs. PDGFR-β-Mock 





34a mimics. b Expression 
level of PDGFR-β mRNA 
was detected with real-time 
qPCR after transfection with 
miR-34a mimics or miRNA-
negative control. Normal: 
normal group; Con: miRNA-
negative control group; Mimics: 
miR-34a mimics. c Protein 
expression levels of PDGFR-β 
and phospho-PDGFR-β were 
detected with Western blot 
after transfection with miR-34a 
mimics or miRNA-negative 
control. Data are means of three 
separate experiments ± SD. 
*, #p < 0.05 vs. normal group 
and Con group, n = 3. Normal: 
normal group; Con: miRNA-
negative control group; Mimics: 
miR-34a mimics. d Protein 
expression levels of PDGFR-β 
and phospho-PDGFR-β were 
detected with Western blot on 
day 0, day 7, and day 14 in 
anti-Thy1 model rats. Data are 
means of three separate experi-
ments ± SD. *p < 0.05 vs. day 
0 and day 14, n = 3
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the proliferation rate of mesangial cells cultured with 
20 % FBS was significantly lower than the control group 
(p < 0.05) and no difference with 10 % FBS culture group 
(p > 0.05) (Fig. 8a). Compared with the 10 % FBS group 
and 20 % FBS control group, the G0/G1 phase of RMCs 
cultured with 20 % FBS after miR-34a mimics transfection 
was extended, and the G2/M phase was reduced (Fig. 8b; 
Table 7). Compared with 20 % FBS control group, protein 
levels of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 
were significantly decreased in 20 % FBS-cultured RMC 
after miR-34a mimics transfection (p < 0.05) (Fig. 8c). Lev-
els of the Ras/MAPK signaling pathway proteins, K-RAS, 
Raf1, MEK1, and ERK1/2, were determined. Com-
pared with the 20 % FBS control group, K-RAS and total 
MEK1 protein levels of miR-34a mimics were decreased 
(p < 0.05), and the phosphorylated protein levels of Raf1, 
MEK1, ERK1/2 were significantly decreased (p < 0.05) 
(Fig. 8c). Compared with 20 % FBS-cultured group, which 
was transfected with miR-34a mimics, p27kip1 in the RMCs 
cultured with 20 % FBS was decreased (p < 0.05) (Fig. 8c). 
These results indicate that miR-34a directly suppressed the 
20 % FBS-stimulated RMC proliferation.  
Discussion
MsPGN is divided into IgA and non-IgA nephropathy, 
and the main pathological changes associated with this 
condition are diffuse proliferation of GMCs and different 
degrees of ECM accumulation [1, 2, 24]. IgA nephropathy 
Fig. 5  Expression of G0/G1 
phase cell cycle-related proteins 
in RMCs after transfection with 
miR-34a mimics. a MiRNA 
expression levels of cyclin 
D1, cyclin E, CDK2, CDK4, 
CDk6, p27kip1 were detected 
with qRT-PCR. *p < 0.05 vs. 
normal (normal group) and 
Con (miRNA-negative control 
group). b Proteins expression 
levels of cyclin D1, cyclin E, 
CDK2, CDK4, CDk6, p27kip1 
were detected with Western 
blot. Data are means of three 
separate experiments ± SD. 
a,b,c,d,e,fp < 0.05 vs. normal 
group and Con group, n = 3. 
Mimics represented miR-34a 
mimics. c Effect of miR-34a 
on expression of cyclin E. Data 
are means of three separate 
experiments ± SD. *p < 0.01 
vs. Mock (psiCHECK-vector) 
and Con (psiCHECK-cyclin 
E + negative control). Mimics: 
psiCHECK-cyclin E + miR-34a 
mimics. d Effect of miR-34a 
on expression of CDK2. Data 
are means of three separate 
experiments ± SD. #p < 0.01 vs. 
Mock (psiCHECK-vector) and 
Con (psiCHECK-CDK2 + neg-
ative control). Mimics: 
psiCHECK-CDK2 + miR-34a 
mimics
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is the most common type of glomerulonephritis globally 
[25–27], and occurs mainly among Asians, especially the 
Japanese and Chinese [28–36]. A study of 13,519 Chinese 
renal biopsies found that primary MsPGN accounted for 
70.88 % of all cases of glomerular diseases. IgA nephropa-
thy comprised 45.26 % of the primary glomerular diseases, 
while non-IgA mesangial proliferative lesions comprised 
25.62 % [37]. The risk factors associated with inflamma-
tory reactions have not been determined. Mesangial cells 
are not only target cells of immune injury, but also prolif-
erate under the influence of various stimulatory molecules, 
release inflammatory factors, and ECM components, and 
further promote kidney damage, ultimately leading to glo-
merular sclerosis and interstitial fibrosis.
miR-34 was first discovered in C. elegans in 2001 [14] 
and is associated with a variety of organ and tumor hyper-
plasias [15–20]. Therefore, this study aimed to investigate 
the role of miR-34a in proliferative glomerulonephritis. 
We first established an anti-Thy1 MsPGN rat model. In the 
anti-Thy1 glomerulonephritis rat model, we detected miR-
34a expression in kidney tissues at various time points and 
found that miR-34a level gradually decreased as prolifera-
tion increased, then returned to normal levels when mesan-
gial proliferation normalized. This indicates that miR-34a 
likely plays a suppressive role in RMC proliferation.
We found that the cell proliferation rate was lower in the 
miR-34a-transfected RMC group than in the control group, 
indicating that miR-34a inhibits the proliferation of RMCs. 
We then used flow cytometry to evaluate the influences of 
miR-34a on the cell cycle. In the miR-34a-transfected cells, 
G1/G0 was lengthened and the G2+M and S phases were 
shortened. Thus miR-34a can extend the G1 phase and 
inhibit cell proliferation. The above results are consistent 
with those reported for miR-34a in other tissues and tumors 
[16, 38, 39].
Fig. 6  Expression levels of Ras/MAPK signaling pathway-related 
proteins were detected with Western blot in RMCs after transfec-
tion with miR-34a mimics. a Protein expression levels of K-ras, 
Raf-1, p-Raf-1, MEK1, p-MEK1, ERK, p-ERK were detected with 
Western blot. Data are means of three separate experiments ± SD. 
a,b,c,dp < 0.05 vs. normal group and Con group (miRNA-negative con-
trol group), n = 3. Mimics: miR-34a mimics. Renilla luciferase activ-
ity was normalized to firefly luciferase activity. b Protein expression 
levels of MEK1 and p-MEK1 were detected with Western blot. Data 
are means of three separate experiments ± SD. *p < 0.01 vs. day 0 
and day 14, n = 3
Fig. 7  Effects of siPDGFR-β on proliferation, cell cycle, cell cycle 
proteins, and Ras/MAPK signaling pathway molecules in RMCs. a 
Proliferation activity of RMCs after transfection with siPDGFR-β or 
negative control was detected by the Cell Counting Kit-8. *p < 0.05 
vs. normal group and siCON group at 48 h, n = 3; #p < 0.01 vs. 
normal group and siCON group at 72 h, n = 3. N: normal group; 
siCon: negative control group; siPR-β: siPDGFR-β. b FCM analysis 
of cell cycles of RMCs transfected with siPDGR-β or negative con-
trol. *p < 0.05 vs. normal group and siCon. group, n = 3. Normal: 
normal group; siCon: negative control group; siPR-β: siPDGFR-β. 
c Protein expression levels of PDGFR-β, p-PDGFR-β, cyclinD1, 
cyclinE, CDK2, CDK4, CDk6, p27kip1, K-ras, Raf-1, p-Raf-1, MEK1, 
p-MEK1, ERK1/2, p-ERK1/2 were detected with Western blot. Data 
are means of three separate experiments ± SD. a,b,c,d,e,f,g,h,i,j,k.l.mp < 0.
05 vs. normal group and siCon group. Normal: normal group; siCon: 
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The most critical elements that positively regulate the 
G1 phase are cell cycle proteins (cyclins D1 and E). Cell 
cycle proteins and cell cycle protein kinases (CDK2, 
CDK4, and CDK6) are assembled into two types of com-
plex: cyclin D1/CDK4/CDK6 and cyclin E/CDK2 [40, 
41]. The cell cycle protein kinase inhibitor (CKI) p27kip1 
inhibits cyclinD1/CDK4/CDK6 and cyclinE/CDK2 com-
plexes, negatively regulating the cell cycle [42]. In the nor-
mal glomerulus, p27kip1 is highly expressed to maintain a 
steady state in the kidney and avoid over-proliferation [43]. 
The p27kip1 level dropped sharply and returned to baseline 
in the MsPGN model [43]. There was a similar change in 
PDGF-induced cell proliferation [44]. According to flow 
cytometry, miR-34a affects mainly the G0/G1 phase of the 
cell cycle; the main G0/G1 phase proteins cyclin D1, cyclin 
E, CDK2, CDK4, CDK6, and p27kip1 were evaluated in this 
study [1, 45, 46].
MiRanda, TargetScanS, and PicTar were integrated into 
MiRGen online biology prediction software (http://www.
diana.pcbi.upenn.edu/miRGen.html), which is the bioin-
formatics software used most commonly to predict miRNA 
target genes. MiRGen prediction results suggested that 
PDGFR-β may be a direct target gene of miR-34a.
PDGFR is a receptor protein of PDGF. PDGF is clas-
sified into four subtypes, of which PDGF-B and PDGF-D 
are involved in the regulation of cell proliferation through 
PDGFR-β [46]. PDGF and PDGFR-β binding activates 
the Ras/MAPK signaling pathway as well as many down-
stream target genes, such as cyclins D1 and E [1], which 
control cell proliferation. The selective PDGFR tyrosine 
blocker STI157 can block mesangial cell proliferation [47].
We found that the PDGFR-β protein level was markedly 
lower in the miR-34a-transfected RMCs, while the mRNA 
level did not change. The results of the dual-luciferase 
assay indicated that PDGFR-β is a direct target gene of 
miR-34a. We assumed that cyclin E and CDK2 were tar-
get genes of miR-34a. The results of the dual-luciferase 
assay confirmed this hypothesis. MiR-34a not only regu-
lates PDGFR-β expression but also acts directly in con-
junction with cyclin E/CDK2 to regulate the cell cycle and 
influence proliferation. Other studies have confirmed that 
cyclin D1 [21], CDK4 [9], and CDK6 [21, 22] are target 
genes of miR-34a. In our study, there were no changes in 
the mRNA levels of cyclin D1, CDK2, or CDK6 while the 
proteins expression was significantly reduced after miR-
34a transfection; however, the mRNA level of cyclin E was 
decreased in the miR-34a-transfected RMCs. Moreover, 
both p27kip1 protein and mRNA levels were increased in 
the miR-34a-transfected group, which is consistent with the 
effect on mesangial cell proliferation [44, 48].
To further define whether miR-34a regulates down-
stream target genes through the Ras/MAPK signaling path-
way, we used miR-34a mimics to transfect RMCs. The 
total Raf1 and ERK1/2 protein level did not change, but 
those of K-RAS, p-Raf1, MEK1, p-MEK1, and p-ERK1/2 
decreased. A previous study showed that the total Raf1, 
ERK1/2, or MEK1 protein level was unchanged when 
RAS/MAPK signaling pathways were activated. We 
hypothesize that the change in the total MEK1 protein 
level occurred because MEK1 is a target gene of miR-34a 
[23]. PDGFR-β activates the RAS/MAPK signal pathway 
molecules, K-RAS, p-Raf1, p-MEK1, and p-ERK1/2, thus 
affecting the G1 phase [49–52]. Therefore, miR-34a may 
directly suppress PDGFR-β and so regulate the expres-
sion of cell-cycle proteins (CDK and CKI) through the 
RAS/MAPK signaling pathway [1, 45].
To demonstrate that miR-34a modulates the cell cycle 
by directly inhibiting PDGFR-β, we used siPDGFR-β to 
inhibit the expression of PDGFR-β. The results showed 
that the changes in both cell proliferation and the cell 
cycle were identical to those in the miR-34a-transfected 
group after siPDGFR-β transfection. The cell cycle pro-
teins also showed the same trend as in the miR-34a group. 
SiPDGFR-β and miR-34a exert similar influences on 
Table 6  The percentage of mesangial cells in G0/G1, S, and G2/M 
phases
Normal normal group, siCon negative control group, siPR-β 
siPDGFR-β
* p < 0.05 vs. normal group and siCon group
G0–G1 (%) S (%) G2-M (%)
Normal 64.15 ± 2.84 22.68 ± 1.90 13.17 ± 1.88
siCon 62.71 ± 1.61 21.35 ± 2.31 15.59 ± 1.61
siPR-β 76.34 ± 2.32* 14.91 ± 1.57* 8.75 ± 0.84*
Fig. 8  Effect of miR-34a on cell cycle, cell cycle proteins, and the 
Ras/MAPK signaling pathway molecules in the RMCs, which were 
stimulated to proliferate by 20 % FBS. a miR-34a mimics antagonize 
20 % FBS-stimulate mesangial cell proliferation. RMCs cultured by 
10 % FBS or 20 % FBS, and transfected with miR-34a mimics or 
negative control. The proliferation rate was detected by Cell Counting 
Kit-8. a,bp < 0.05 vs. 20 % FBS group and 20 % FBS + Con group 
at 48 h, n = 3; c,dp < 0.01 vs. 20 % FBS group and 20 % FBS + Con 
group at 72 h, n = 3. 10 % FBS: 10 % FBS group; 20 % FBS: 20 % 
FBS group; 20 % FBS + Con: 20 % FBS + negative control; 20 % 
FBS + miR-34a: 20 % FBS + miR-34a mimics. b FCM analysis 
of cell cycles of RMCs transfected with miR-34a mimics or nega-
tive control, n = 3. 10 % FBS: 10 % FBS group; 20 % FBS: 20 % 
FBS group; 20 % FBS + Con: 20 % FBS + negative control; 20 % 
FBS + miR-34a:20 % FBS + miR-34a mimics. c Protein expres-
sion levels of PDGFR-β, p-PDGFR-β, cycliyD1, cyclinE, CDK2, 
CDK4, CDk6, p27kip1, K-ras/Raf-1, p-Raf-1, MEK1, p-MEK1, 
ERK1/2, p-ERK1/2 were detected with Western blot. Data are means 
of three separate experiments ± SD. a,b,c,d,e,f,g,h,i,j,k,lp < 0.05 vs. 20 % 
FBS + mimics group. 10 % FBS: 10 % FBS group; 20 % FBS: 20 % 
FBS group; 20 % FBS + Con: 20 % FBS + negative control; 20 % 
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PDGFR-β and the cell cycle. Therefore, miR-34a can affect 
the G0/G1 phase through inhibition of PDGFR-β.
We have confirmed that miR-34a can directly inhibit the 
target gene PDGFR-β and in turn affect the normal RMC 
proliferation function by suppressing the G0/G1 phase. 
Here we use high concentrations of serum (20 % serum) 
to stimulate mesangial cell proliferation, and then use miR-
34a to antagonize this phenomenon. The results are clear 
that high concentrations of serum could accelerate cell pro-
liferation, however, the use of miR-34a together with a high 
concentration of serum in the cell, the cell proliferation rate 
return to normal levels for 10 % serum culture group. Thus, 
miR-34a can antagonize proliferation of the high concen-
tration serum group.
In conclusion, we found that miR-34a regulates mesan-
gial cell proliferation by directly inhibiting expressions of 
PDGFR-β and factor (MEK1) in the RAS/MAPK signal 
pathway, and by influencing the G0/G1 phase. MiR-34a 
may also affect cell proliferation by directly suppressing 
the expression of cyclin E and CDK2 cell cycle proteins in 
the G0/G1 phase (Fig. 9).
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